Rephrase and rearrange the whole content into a news article. I want you to respond only in language English. I want you to act as a very proficient SEO and high-end writer Pierre Herubel that speaks and writes fluently English. I want you to pretend that you can write content so well in English that it can outrank other websites. Make sure there is zero plagiarism.:
The Food and Drug Administration (FDA) has approved DermaSensor’s groundbreaking AI-powered medical device, marking a pivotal moment as the first artificial intelligence-driven tool designed to assist doctors in identifying common forms of skin cancer.
CBS News reported that the AI medical device, developed Miami-based firm DermaSensor, is engineered to evaluate lesions flagged as suspicious doctors, emphasizing its role as a supplementary diagnostic tool rather than a screening device, according to the FDA.
The handheld, non-invasive DermaSensor uses AI-powered spectroscopy technology to look at the cellular and subcutaneous features of lesions. It gives real-time results using an AI algorithm that has been trained on data from over 4,000 benign and malignant lesions. The device, targeted at primary care physicians, dermatologists, and other medical professionals, provides a “spectral similarity score” to known cases, enhancing a physician’s assessment of moles or lesions.
Revolutionizing Skin Cancer Treatment
DermaSensor, positioned as a high-tech solution for skin cancer assessment, received approval for use in patients aged 40 and older. The FDA stresses the device’s use in conjunction with clinically relevant information, including visual analysis, especially non-dermatologist physicians.
DermaSensor is now FDA CLEARED! After 10 years and $25 million of active research & development, we’re grateful for FDA’s collaboration in reaching this milestone in skin cancer care.
Read the press release at https://t.co/MfqiWFRCJE, and learn more at https://t.co/xbluD42cr1. pic.twitter.com/utOcCfV1PX
— DermaSensor, Inc. (@DermaSensor) January 17, 2024
The device operates through a straightforward process: a doctor identifies a potentially cancerous lesion, the wireless device records it, DermaSensor scans the lesion, and a proprietary algorithm analyzes spectral data, delivering a real-time assessment. Results may recommend further specialist investigation or monitoring without immediate further evaluation.
Cody Simmons, co-founder and CEO of DermaSensor, welcomed the FDA approval, highlighting how predictive and generative AI, spectroscopy, and genetic sequencing are improving disease detection and care.
DermaSensor screens moles for basal cell carcinoma and squamous cell carcinoma, in addition to melanoma, the most deadly skin disease With skin cancer affecting one in five Americans age 70, DermaSensor offers a critical tool for early detection, potentially saving lives and reducing the substantial cost of skin cancer treatment in the U.S., estimated at over $8 billion.
Read Also: New Study Exposes Disturbing Link Between Energy Drinks and Health Issues in Young People
According to the American Academy of Dermatology, skin cancer stands as the most widespread type of cancer in the United States, with an expected one in five Americans developing the condition in their lifetime. About 9,500 people in the United States receive skin cancer diagnoses every day, which adds up to an estimated annual number of over 3 million Americans who have nonmelanoma skin cancer. Increased exposure to UV radiation from sunlight or indoor tanning, along with a personal history of the disease, elevates the risk of all types of skin cancer.
The FDA approval comes with a stipulation for DermaSensor to conduct additional validation testing in patients from diverse demographic groups, including those at lower risk of skin cancer, ensuring the device’s effectiveness across a broad population.
AI Now Being Used in Identifying Best Cancer Therapy
In another development, UC San Diego School of Medicine researchers are employing AI to improve cancer therapy. Cancer Discovery research uses AI to suggest the best cancer therapies based on tumor gene mutation complexity.
The AI, identifying 90 crucial genes for treatment decisions, aims to assist doctors in navigating the intricate landscape of cancer mutations and treatment options. Trey Ideker, Ph.D., emphasizes transparency and validation, ensuring the system explains its rationale and undergoes scrutiny experts, potentially refining treatment decisions and extending life expectancy for cancer patients, as per a CBS 8 report.
Related Article: Chinese Scientists Develop Lethal COVID-19 Strain, Raising Concerns About Spillover Risk to Humans
ⓒ 2023 TECHTIMES.com All rights reserved. Do not reproduce without permission.